<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495324</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FVO-CT-401</org_study_id>
    <nct_id>NCT02495324</nct_id>
  </id_info>
  <brief_title>Fimasartan Achieving SBP Target (FAST) Study</brief_title>
  <acronym>FAST</acronym>
  <official_title>A Randomized, Double-blind, Active Control, 3-parallel Group, Forced Titration, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Fimasartan Versus Valsartan Monotherapy in Patients With Mild to Moderate Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Fimasartan compared to&#xD;
      Valsartan and Olmesartan(reference group) in patients with mild to moderate essential&#xD;
      hypertension. Patients have 2 weeks of placebo run-in and wash out period, 2 weeks of taking&#xD;
      required dose and 4 weeks of taking double dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, active control, 3-parallel group comparison clinical study to&#xD;
      evaluate the anti-hypertensive efficacy and safety of Fimasartan in patients with mild to&#xD;
      moderate hypertension. Approximately 360 patients will be enrolled in 8 centers in South&#xD;
      Korea. This study has planned 6 visits during 8 weeks.(2 weeks of placebo run-in and wash&#xD;
      out, 2 weeks of treatment and 4 weeks of forced titration) All of the subjects who agreed to&#xD;
      participate in this study and gave written informed consent voluntarily are assessed the&#xD;
      inclusion and exclusion criteria and receive the investigational product(placebo) at&#xD;
      screening visit. During more than 14 days of placebo run-in and wash out period, subjects&#xD;
      have to stop the previous anti-hypertensive drug. After placebo run-in and wash out period,&#xD;
      Subjects are assessed the final eligibility and started measuring ambulatory blood pressure&#xD;
      for 24 hours. Subjects who determined to be appropriate for this study are allocated to&#xD;
      experimental group(Fimasartan 60mg) or control group(Valsartan 80mg) or Reference&#xD;
      group(Olmesartan 10mg) randomly at ratio 3:3:1.Subjects take their investigational products&#xD;
      daily for 2 weeks and double dose for 4 weeks. The placebo period will be single-blinded and&#xD;
      the treatment allocation in this study will be double-blinded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of sitting SBP from baseline after taking investigational products for 6 weeks.</measure>
    <time_frame>6 weeks from baseline visit</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">369</enrollment>
  <condition>Essential,Hypertension</condition>
  <arm_group>
    <arm_group_label>Fimasartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo daily for 2 weeks and Fimasartan 60mg daily for 2 weeks and 120mg daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo daily for 2 weeks and Valsartan 80mg daily for 2 weeks and 160mg daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olmesartan medoxomil</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Reference group. Placebo daily for 2 weeks and Olmesartan 10mg daily for 2 weeks and 20mg daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 weeks of placebo PO daily</description>
    <arm_group_label>Fimasartan</arm_group_label>
    <arm_group_label>Olmesartan medoxomil</arm_group_label>
    <arm_group_label>Valsartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan</intervention_name>
    <description>60mg 1 tab PO daily for 2 weeks and 120mg 1 tab PO daily for 4 weeks</description>
    <arm_group_label>Fimasartan</arm_group_label>
    <other_name>Kanarb Tab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>80mg 1 tab PO daily for 2 weeks and 160mg 1 tab PO daily for 4 weeks</description>
    <arm_group_label>Valsartan</arm_group_label>
    <other_name>Diovan Tab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil</intervention_name>
    <description>10mg 1 tab PO daily for 2 weeks and 20mg 1 tab PO daily for 4 weeks</description>
    <arm_group_label>Olmesartan medoxomil</arm_group_label>
    <other_name>Olmetec Tab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who voluntarily signed informed consent for participating in this clinical&#xD;
             trial&#xD;
&#xD;
          2. Male and female between 19 and 70 years old&#xD;
&#xD;
          3. Subjects whose mean sitting SBP(siSBP) of 3 measurements is above 140mmHg at visit 2&#xD;
             with mild to moderate essential hypertension (Subjects who have not taken&#xD;
             anti-hypertensive drugs within 3 months should have mean siSBP above 140mmHg at visit&#xD;
             1)&#xD;
&#xD;
          4. Subject who can understand the trial procedures and be willing to cooperate the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe hypertension patients with mean siSBP ≥ 180mmHg or siDBP ≥110mmHg at the&#xD;
             assessment of Screening visit(Visit1) and Baseline visit (Visit2).&#xD;
&#xD;
          2. Patients whose difference between maximum and minimum among 3 times of blood pressure&#xD;
             measurement is over 20mmHg(siSBP) or 10mmHg(siDBP) at visit1 and visit2.&#xD;
&#xD;
          3. Patients whose medication compliance is under 70% at visit 2.&#xD;
&#xD;
          4. Secondary hypertension patients, but not limited to the following diseases (example:&#xD;
             renovascular disease, adrenal medullary and cortical hyperfunctions, coarctation of&#xD;
             the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis,&#xD;
             Cushing's syndrome, pheochromocytoma, polycystic kidney disease, etc).&#xD;
&#xD;
          5. Patients who have postural hypotension with manifestation.&#xD;
&#xD;
          6. Subjects with severe insulin-dependent Diabetes Mellitus(DM) or uncontrolled DM(HbA1c&#xD;
             &gt; 9% at screening visit, modified dosage of an oral hypoglycemic agent within 12 weeks&#xD;
             prior to screening visit, or currently use of active insulin treatment).&#xD;
&#xD;
          7. History of malignant tumor including leukemia and lymphoma in the past 5 years.&#xD;
&#xD;
          8. Subjects with chronic inflammatory disease requiring an chronic anti-inflammatory&#xD;
             therapy, past or current medical history with wasting disease, autoimmune diseases&#xD;
             (e.g. rheumatoid arthritis, systemic lupus erythematosus) or connective tissue&#xD;
             disease.&#xD;
&#xD;
          9. Medical history with hypersensitivity to angiotensin II antagonist.&#xD;
&#xD;
         10. Clinically significant renal and liver disorders such as dialysis, cirrhosis, biliary&#xD;
             obstruction, cholestasis and liver failure. Patients who have below abnormality in the&#xD;
             laboratory results at screening visit.&#xD;
&#xD;
               -  Creatinine clearance(Cockroft-Gault)&lt;30mL/min&#xD;
&#xD;
               -  ALT, AST ≥ 2 times upper normal limit&#xD;
&#xD;
               -  Clinically significant hypokalemia(K&lt;3.5mmol/L) or hyperkalemia(K&gt;5.5mmol/L)&#xD;
&#xD;
         11. Subjects have history of any of the followings within the past 6 months or determined&#xD;
             clinically significant by investigators.&#xD;
&#xD;
               -  Severe heart disease (Heart failure New York Heart Association(NYHA) class 3 and&#xD;
                  4), ischemic heart disease (angina pectoris, myocardial infarction), peripheral&#xD;
                  vascular disease, percutaneous transluminal coronary angioplasty or coronary&#xD;
                  artery bypass graft.&#xD;
&#xD;
               -  Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery&#xD;
                  disease, aortic stenosis, hemodynamically significant aortic valve stenosis, or&#xD;
                  mitral valve stenosis.&#xD;
&#xD;
               -  Clinically significant ventricular tachycardia, atrial fibrillation, atrial&#xD;
                  flutter or any other clinical significant arrhythmia.&#xD;
&#xD;
               -  Severe cerebrovascular disorder(e.g.stroke, cerebral infarction or cerebral&#xD;
                  hemorrhage)&#xD;
&#xD;
         12. Subjects with known moderate or malignant retinosis in the past 6 months (e.g. retinal&#xD;
             hemorrhage, visual disturbance or retinal microaneurysm)&#xD;
&#xD;
         13. Subjects with history of abusing drugs or alcohol within the past 2 years.&#xD;
&#xD;
         14. Pregnant women or lactating female.&#xD;
&#xD;
         15. Subjects with following surgical and internal disease that may affect absorption,&#xD;
             distribution, metabolism or excretion of drugs and have conditions which include the&#xD;
             following (but are not limited to): history of major gastrointestinal surgeries&#xD;
             including gastrectomy, gastro-enterostomy or bowel resection, gastrointestinal bypass&#xD;
             graft and stabling; current active gastritis, gastrointestinal and rectal bleeding,&#xD;
             presence of active inflammatory bowel syndrome within the past 12 months.&#xD;
&#xD;
         16. Subjects with shock, depletion of body fluid or sodium ion not able to correct.&#xD;
&#xD;
         17. Subjects with hereditary disorders of galactose intolerance, Lapp lactase deficiency&#xD;
             or glucose-galactose malabsorption.&#xD;
&#xD;
         18. Medical history with clinically significant hypersensitivity to any components or&#xD;
             other drugs on the investigational product or additives(yellow4 and yellow 5).&#xD;
&#xD;
         19. Subjects planning pregnancy or childbearing potential who are not using effective&#xD;
             contraceptive methods.&#xD;
&#xD;
         20. Subjects who are participating in another trial or took other investigational product&#xD;
             within 12 weeks prior to screening visit.&#xD;
&#xD;
         21. Subjects with other reasons not specified above and ineligible to participate in this&#xD;
             clinical trial at discretion of study investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KI-BAE SEUNG, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiovascular center, Seoul St.Mary's Hospital, The Catholic University of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Banpo-dong, Seocho-gu</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Incheon St.Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <state>Bupyeong-gu</state>
        <zip>403-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St. Paul's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Dongdaemun-gu</state>
        <zip>130-709</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St.Vincent's Hospital.</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>442-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea,Uijeongbu St.Mary's Hospital</name>
      <address>
        <city>Uijeongbu</city>
        <state>Gyeonggi-do</state>
        <zip>480-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Daejeon St. Mary's Hospital</name>
      <address>
        <city>Daejeon</city>
        <state>Jung-gu/Daeheung-ro</state>
        <zip>301-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Bucheon St.Mary's Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Kyunggi-Do</state>
        <zip>420-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea,Yeouido St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Yeongdeungpo-gu</state>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 7, 2015</study_first_submitted>
  <study_first_submitted_qc>July 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2015</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

